Squarepoint
ACRS icon

Squarepoint’s Aclaris Therapeutics ACRS Stock Holding History

Squarepoint’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$472K Buy
+89,811
New +$513K ﹤0.01% 3434
2025
Q3 		– Sell
-390,583
Closed -$555K – 4311
2025
Q2 		$555K Buy
390,583
+41,666
+12% +$56.4K ﹤0.01% 3185
2025
Q1 		$534K Buy
348,917
+56,025
+19% +$120K ﹤0.01% 3237
2024
Q4 		$726K Buy
292,892
+152,312
+108% +$379K ﹤0.01% 3371
2024
Q3 		$162K Buy
140,580
+45,893
+48% +$56.3K ﹤0.01% 3761
2024
Q2 		$104K Buy
+94,687
New +$111K ﹤0.01% 3789
2024
Q1 		– Sell
-10,378
Closed -$10.9K – 3948
2023
Q4 		$10.9K Buy
+10,378
New +$31.7K ﹤0.01% 3927
2021
Q4 		– Sell
-15,834
Closed -$285K – 3114
2021
Q3 		$285K Buy
+15,834
New +$254K ﹤0.01% 2285
2021
Q2 		– Sell
-8,537
Closed -$215K – 3167
2021
Q1 		$215K Buy
+8,537
New +$167K ﹤0.01% 2660
2020
Q1 		– Sell
-83,924
Closed -$159K – 1802
2019
Q4 		$159K Buy
+83,924
New +$139K ﹤0.01% 2269
2019
Q3 		– Sell
-58,902
Closed -$129K – 2300
2019
Q2 		$129K Buy
58,902
+12,996
+28% +$70.8K ﹤0.01% 2189
2019
Q1 		$275K Sell
45,906
-66,684
-59% -$442K ﹤0.01% 1811
2018
Q4 		$832K Buy
112,590
+81,220
+259% +$837K 0.01% 995
2018
Q3 		$455K Buy
31,370
+16,995
+118% +$291K 0.01% 1344
2018
Q2 		$287K Sell
14,375
-24,683
-63% -$456K ﹤0.01% 1395
2018
Q1 		$684K Buy
39,058
+19,442
+99% +$412K 0.01% 965
2017
Q4 		$484K Buy
+19,616
New +$478K 0.01% 1230
2017
Q1 		– Sell
-10,739
Closed -$291K – 1487
2016
Q4 		$291K Buy
+10,739
New +$274K 0.01% 1167

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Panagora Asset Management
Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Three Bridge Wealth Advisors
Three Bridge Wealth Advisors Los Altos, California $469M AUM 10.36% 1-Year Est. Return

Squarepoint's ACRS Position: Q3 2026 in Review

Squarepoint opened a new position in Aclaris Therapeutics (ACRS) in Q3 2026: 89,811 shares worth $472K. The stake represents ﹤0.01% of the portfolio and ranks #3434 among its holdings. This is a return to the name: Squarepoint previously reported a position in ACRS as recently as Q2 2025.

Squarepoint first reported a position in ACRS in Q4 2016 and has held it in 18 quarters since. The position peaked at $832K in Q4 2018. 82 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • Squarepoint held 89,811 shares of Aclaris Therapeutics worth $472K as of Q3 2026.
  • Aclaris Therapeutics was a new Squarepoint position in Q3 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3434 holding.
  • Squarepoint first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 18 quarters since.
  • Squarepoint's Aclaris Therapeutics position peaked at $832K in Q4 2018.
  • 82 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.